L · 0KF3.L
Palatin Technologies, Inc.
- Sector
- Healthcare · Medical - Pharmaceuticals
- Headquarters
- Cranbury, NJ 08512
- Website
- palatin.com
Price · as of 2025-06-30
$21.90
Market cap 19.48M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $259.00 | +1,082.65% |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $0.00 | $923.70 | |||
| 2012 | $0.00 | $763.20 | |||
| 2013 | $0.00 | $295.60 | |||
| 2014 | |||||
| 2015 | $0.00 | ||||
| 2016 | |||||
| 2017 | $0.00 | ||||
| 2018 | $14.20 | $130.60 | |||
| 2019 | $25.10 | $0.00 | |||
| 2020 | $0.00 | $155.70 | |||
| 2021 | $612.88 | $423.38 | $0.00 | $0.00 | $636.30 |
| 2022 | $335.70 | $223.83 | $0.00 | $0.00 | |
| 2023 | $105.50 | $71.16 | $44.27 | $0.00 | $0.00 |
| 2024 | $73.56 | $42.90 | $55.77 | $0.00 | $0.00 |
| 2025 | $10.02 | $346.97 |
AI valuation
Our deep-learning model estimates Palatin Technologies, Inc.'s (0KF3.L) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $259.00
- Current price
- $21.90
- AI upside
- +1,082.65%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
About Palatin Technologies, Inc.
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
- CEO
- Carl Spana
- Employees
- 30
- Beta
- -0.24
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $21.90) − 1 = — (DCF, example).